Inotek Pharmaceuticals to Present at the 2016 Ophthalmology Innovation Summit
October 07 2016 - 07:00AM
Business Wire
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the “Company”
or “Inotek”), a clinical stage biopharmaceutical company focused on
the discovery, development and commercialization of therapies for
ocular diseases, today announced that David P. Southwell, President
and Chief Executive Officer of Inotek, will present at the 2016
Ophthalmology Innovation Summit at the American Academy of
Ophthalmology (OIS@AAO) annual meeting on Thursday, October 13,
2016, at 3:18 p.m. Central Time at the Hyatt Regency Chicago.
About Inotek Pharmaceuticals CorporationInotek
Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
therapies for glaucoma and other eye diseases. The Company’s lead
product candidate, trabodenoson, is a first-in-class selective
adenosine mimetic currently in Phase 3
development. Trabodenoson was developed in Inotek’s
laboratories and is designed to restore the eye’s natural pressure
control mechanism. Additionally, the Company is evaluating the
potential for selective adenosine mimetics to address optic
neuropathies and other degenerative retinal diseases. For more
information, please visit www.inotekpharma.com. The inclusion of
our website address here and elsewhere in this press release does
not include or incorporate by reference the information on our
website into this press release.
Forward-Looking StatementsThis press release contains
forward-looking statements, which are subject to substantial risks,
uncertainties and assumptions. You should not place reliance on
these statements often include words such as "believe," "expect,"
"anticipate," "intend," "plan," "estimate," "seek," "will," "may"
or similar expressions. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, the Company cannot guarantee such outcomes.
Accordingly, you should not place undue reliance on these
forward-looking statements. All such statements speak only as of
the date made, and the Company undertakes no obligation to update
or revise publicly any forward-looking statements, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161007005074/en/
Inotek Contact:Claudine Prowse, PhD, 781-552-4305Vice
President, Strategy and IROIR@inotekpharma.comorInvestor
Contact:MacDougall Biomedical CommunicationsChris Erdman,
781-235-3060cerdman@macbiocom.comorMedia Contact:MacDougall
Biomedical CommunicationsKaren Sharma,
781-235-3060ksharma@macbiocom.com
INOTEK PHARMACEUTICALS CORP (NASDAQ:ITEK)
Historical Stock Chart
From Feb 2024 to Mar 2024
INOTEK PHARMACEUTICALS CORP (NASDAQ:ITEK)
Historical Stock Chart
From Mar 2023 to Mar 2024